November 30, 2016 - By Ruchi Gupta
In an analyst report shared with investors on Wednesday, 30 November, Alnylam Pharma (NASDAQ:ALNY) stock “Buy” was reconfirmed at Chardan Capital Markets. They currently have a $89 TP on the stock. Chardan Capital Markets’s TP would suggest a potential upside of 93.35% from the company’s last stock price.
Out of 14 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 57% are positive. $184 is the highest target while $34 is the lowest. The $84.21 average target is 82.95% above today’s ($46.03) stock price. Alnylam Pharmaceuticals has been the topic of 30 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was downgraded by JP Morgan on Thursday, October 6 to “Neutral”. Goldman Sachs maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, October 6 with “Neutral” rating. The rating was maintained by JMP Securities with “Outperform” on Friday, August 28. The firm has “Hold” rating given on Saturday, August 22 by TheStreet. The company was downgraded on Thursday, October 6 by Barclays Capital. Chardan Capital Markets maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, October 6 with “Buy” rating. As per Thursday, October 6, the company rating was maintained by Stifel Nicolaus. The firm has “Mkt Perform” rating by Leerink Swann given on Thursday, October 6. As per Friday, August 5, the company rating was maintained by JP Morgan. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Outperform” rating given on Tuesday, May 3 by Leerink Swann.
The stock increased 1.59% or $0.72 during the last trading session, hitting $46.03. About 20 shares traded hands. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 32.93% since April 27, 2016 and is downtrending. It has underperformed by 38.16% the S&P500.
Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 9. They expect $-1.35 EPS, down 26.17% or $0.28 from last year’s $-1.07 per share. After $-1.21 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 11.57% negative EPS growth.
Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.25, from 1.27 in 2016Q1. The ratio turned negative, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Zurcher Kantonalbank (Zurich Cantonalbank) owns 9,248 shares or 0.01% of their US portfolio. Pictet Asset Mgmt last reported 42,506 shares in the company. Credit Suisse Ag holds 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 209,295 shares. Eventide Asset Mngmt last reported 0.31% of its portfolio in the stock. Point72 Asia (Hong Kong) Ltd, a Hong Kong-based fund reported 6,435 shares. Kbc Group Nv has 4,469 shares for 0% of their US portfolio. Winfield Associate Inc has 0% invested in the company for 20 shares. Blackrock Institutional Na accumulated 1.93M shares or 0.02% of the stock. The Wisconsin-based Artisan Prtnrs L P has invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Commonwealth Equity Svcs holds 5,704 shares or 0% of its portfolio. Artal Gp Sa reported 710,000 shares or 0.81% of all its holdings. Weiss Multi holds 3,645 shares or 0.02% of its portfolio. The Ontario – Canada-based Td Asset Management has invested 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Teachers Retirement Systems Of The State Of Kentucky holds 183,409 shares or 0.13% of its portfolio. Turner Limited Partnership has 10,370 shares for 0.18% of their US portfolio.
Insider Transactions: Since July 19, 2016, the stock had 1 insider purchase, and 1 insider sale for $918,262 net activity. MARAGANORE JOHN sold $1.95 million worth of stock. $1.03 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares were bought by PYOTT DAVID E I.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $3.74 billion. The Firm is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs).
According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”
Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.
More recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data” on November 04, 2016. Also Fool.com published the news titled: “Why Alnylam Pharmaceuticals, Inc. Took a 47.5% Dive in October” on November 07, 2016. Businesswire.com‘s news article titled: “Alnylam Pharmaceuticals and The Medicines Company Announce Publication of …” with publication date: November 13, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta